The AKAP8 Knockout Jurkat Polyclonal Cells are a genetically modified human T lymphocyte population generated by CRISPR/Cas9-mediated disruption of the AKAP8 gene. This product provides a heterogeneous pool of Jurkat cells with targeted AKAP8 gene knockout, enabling functional studies without clonal selection. The polyclonal format preserves population-level diversity while eliminating AKAP8 expression, making it suitable for investigating the gene’s role in signaling and leukemogenesis.
The Jurkat cell line, an immortalized T lymphoblastoid line derived from the peripheral blood of a patient with acute T cell leukemia, serves as a well-established model for T lymphocyte biology and leukemia research. Jurkat cells are widely utilized to study T cell receptor (TCR) signaling, apoptosis, and cytokine production, and they display characteristic activation pathways relevant to immune response and oncogenic transformation. Their leukemic origin provides a pertinent background for exploring molecular mechanisms in hematologic malignancies.
AKAP8 encodes an A-kinase anchoring protein that scaffolds protein kinase A (PKA) to the nuclear matrix and splicing speckles, spatially regulating cAMP-dependent phosphorylation. It interacts with the PKA RII?? regulatory subunit and spliceosome components DDX5 and SFRS1, as well as matrin-3 and protein phosphatase 1 (PP1). Positioned downstream of cAMP and mitogenic signals, AKAP8 directs PKA to phosphorylate substrates such as the transcription factor CREB and cell cycle regulators, participating in chromatin remodeling, RNA splicing, and cell cycle progression. By tethering PKA in proximity to its targets, AKAP8 modulates mRNA processing and transcriptional responses critical for cell proliferation and differentiation.
In Jurkat cells, AKAP8-mediated PKA compartmentalization is implicated in TCR signaling and leukemic cell maintenance. Knockout of AKAP8 disrupts the precise localization of PKA, potentially impairing phosphorylation of downstream effectors such as CREB and altering spliceosome function, which may lead to aberrant gene expression and growth deficits. This model is therefore valuable for dissecting the contribution of AKAP8 to T cell leukemogenesis and cAMP-driven immune modulation, as well as for investigating its roles in solid tumor biology where AKAP8 dysregulation has been observed.
Researchers can employ these AKAP8 knockout polyclonal Jurkat cells in a range of applications, including examining PKA compartmentalization in T lymphocytes, evaluating AKAP8’s function in leukemic transformation, and screening compounds that disrupt the AKAP8-PKA interaction. Representative assays include western blotting for AKAP8 and phospho-PKA substrates, RT-qPCR for T cell activation markers, flow cytometry for apoptosis using Annexin V staining, RNA sequencing to detect splicing alterations, and co-immunoprecipitation to assess AKAP8-PKA complexes. For further technical specifications or customized cell solutions, please contact Ascent Research.
